Control of meningococcal meningitis with meningococcal vaccines.
نویسنده
چکیده
The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies. Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity. In controlled field trials in Army recruits, group C polysaccharide vaccines were highly effective in preventing group C disease. Following its use as a routine immunization in recruits in October 1971 group C meningococcal disease has been almost completely eliminated from Army training centers. Group A vaccine has been field tested in Egyptian school children with great success. Group B polysaccharide has failed to induce bactericidal antibodies in humans and, therefore, new research is underway to attempt to develop a cell wall protein antigen as a vaccine against group B disease.
منابع مشابه
Immunological Aspect of Meningococcal disease: An overview in Host- Bacteria Interaction
Meningococcal disease remains a significant global public health and is unique among causes of bacterial meningitis and sepsis where it not only causes sporadic disease but also outbreaks. Meningococcal disease has a rapid onset with high mortality. The understanding of immunopathogenesis is crucial for development of novel therapeutic strategies and vaccines designed against meningococcal dise...
متن کاملUse of fractional doses of meningococcal polysaccharide vaccines for the control of epidemic meningococcal meningitis in Africa in a context of vaccine shortage
متن کامل
1 Meningococcal Vaccines : Current Status and 2 Emerging Strategies 3
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis 8 is a public health burden to both developed and developing countries throughout the world. There 9 are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined 10 conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the 11 pathogen. ...
متن کاملPresent situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
BACKGROUND In Italy one third of bacterial meningitis are caused by Neisseria meningitidis. In March 2005, the Regional Health Authority of Tuscany included the meningococcal serogroup C conjugate (MCC) vaccine in the recommended vaccination program with a schedule of three doses to all newborns at 3, 5 and 13 months of age (from 2008 amended to a single dose at 13 months) and a single catch-up...
متن کاملAn evaluation of emerging vaccines for childhood meningococcal disease
BACKGROUND Meningococcal meningitis is a major cause of disease worldwide, with frequent epidemics particularly affecting an area of sub-Saharan Africa known as the "meningitis belt". Neisseria meningitidis group A (MenA) is responsible for major epidemics in Africa. Recently W-135 has emerged as an important pathogen. Currently, the strategy for control of such outbreaks is emergency use of me...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Yale Journal of Biology and Medicine
دوره 48 شماره
صفحات -
تاریخ انتشار 1975